The EUTOS score identifies chronic myeloid leukeamia patients with poor prognosis treated with imatinib first or second line

Leukemia Research

Volumn 36, Issue 9, 2012, Pages

  Breccia, Massimo ^a   Finsinger, Paola ^a   Loglisci, Giuseppina ^a   Latagliata, Roberto ^a   Mancini, Marco ^a   Salaroli, Adriano ^a   Serrao, Alessandra ^a   Zacheo, Irene ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

BASOPHIL; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG POTENCY; EUTOS SCORE; HIGH RISK PATIENT; HUMAN; LETTER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RATING SCALE; RISK ASSESSMENT; SEX DIFFERENCE; SPLEEN SIZE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DIAGNOSTIC TECHNIQUES AND PROCEDURES; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PIPERAZINES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PYRIMIDINES; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84864011127     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.05.011     Document Type: Letter

References (6)

1. Breccia M., Alimena G. Bringing prognostic scores for chronic myeloid leukemia patients up to date. Expert Rev Hematol 2011, 4:373-375.
2. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
3. Hasford J., Baccarani M., Hoffmann V., et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011, 118:686-692.
4. Marin D., Ibrahim A.R., Goldman J.M. European treatment and out come study (EUTOS) score for chronic myeloid leukemia still require more confirmation. J Clin Oncol 2011, 29:3944-3945.
5. Steegmann J.L., Casado L.F. The new EUTOS score has prognostic value in the treatment of chronic myeloid leukemia (CML) outside clinical trials. Blood 2012, e-letter January 27.
6. Giles F.J., Rosti G., Ossenkoppele G., et al. A phase IIIb multicentre open-label study of nilotinib in adult patients with newly diagnosed BCR-ABL positive chronic myeloid leukemia (CML) in chronic phase (CP): a European clinical iniziative with EUTOS collaboration for standardisation of molecular remission. Blood 2011, 118. abs 2759.